BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 35025619)

  • 1. Mutant
    Singh A; Mencia-Trinchant N; Griffiths EA; Altahan A; Swaminathan M; Gupta M; Gravina M; Tajammal R; Faber MG; Yan L; Sinha E; Hassane DC; Hayes DN; Guzman ML; Iyer R; Wang ES; Thota S
    JCO Precis Oncol; 2022 Jan; 6():e2100309. PubMed ID: 35025619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy.
    Hsu JI; Dayaram T; Tovy A; De Braekeleer E; Jeong M; Wang F; Zhang J; Heffernan TP; Gera S; Kovacs JJ; Marszalek JR; Bristow C; Yan Y; Garcia-Manero G; Kantarjian H; Vassiliou G; Futreal PA; Donehower LA; Takahashi K; Goodell MA
    Cell Stem Cell; 2018 Nov; 23(5):700-713.e6. PubMed ID: 30388424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonal hematopoiesis with
    Stelmach P; Richter S; Sauer S; Fabre MA; Gu M; Rohde C; Janssen M; Liebers N; Proynova R; Weinhold N; Raab MS; Goldschmidt H; Besenbeck B; Pavel P; Laier S; Trumpp A; Dietrich S; Vassiliou GS; Müller-Tidow C
    Haematologica; 2023 Dec; 108(12):3308-3320. PubMed ID: 37381752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PPM1D in Solid and Hematologic Malignancies: Friend and Foe?
    Zhang L; Hsu JI; Goodell MA
    Mol Cancer Res; 2022 Sep; 20(9):1365-1378. PubMed ID: 35657598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with
    Bergsma H; van Lom K; Raaijmakers MHGP; Konijnenberg M; Kam BLBLR; Teunissen JJM; de Herder WW; Krenning EP; Kwekkeboom DJ
    J Nucl Med; 2018 Mar; 59(3):452-458. PubMed ID: 28775205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein phosphatase, Mg
    Husby S; Hjermind Justesen E; Grønbæk K
    Br J Haematol; 2021 Feb; 192(4):697-705. PubMed ID: 33616916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonal hematopoiesis of indeterminate potential and clonal cytopenias of undetermined significance: 2023 update on clinical associations and management recommendations.
    Mangaonkar AA; Patnaik MM
    Am J Hematol; 2023 Jun; 98(6):951-964. PubMed ID: 36938794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
    Carlsen EA; Fazio N; Granberg D; Grozinsky-Glasberg S; Ahmadzadehfar H; Grana CM; Zandee WT; Cwikla J; Walter MA; Oturai PS; Rinke A; Weaver A; Frilling A; Gritti S; Arveschoug AK; Meirovitz A; Knigge U; Sorbye H
    Endocr Relat Cancer; 2019 Feb; 26(2):227-239. PubMed ID: 30540557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors.
    Franch-Expósito S; Mehine M; Ptashkin RN; Bolton KL; Bandlamudi C; Srinivasan P; Zhang L; Goodell MA; Gedvilaite E; Menghrajani K; Sánchez-Vela P; Mandelker D; Comen E; Norton L; Benayed R; Gao T; Papaemmanuil E; Taylor B; Levine R; Offit K; Stadler Z; Berger MF; Zehir A
    JCO Precis Oncol; 2023 Aug; 7():e2300070. PubMed ID: 37561983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience.
    Kesavan M; Turner JH
    Cancer Biother Radiopharm; 2016 Aug; 31(6):189-98. PubMed ID: 27419665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal hematopoiesis in older patients with breast cancer receiving chemotherapy.
    Mayerhofer C; Sedrak MS; Hopkins JO; Li T; Tayob N; Faggen MG; Sinclair NF; Chen WY; Parsons HA; Mayer EL; Lange PB; Basta AS; Perilla-Glen A; Lederman RI; Wong AR; Tiwari A; McAllister SS; Mittendorf EA; Gibson CJ; Burstein HJ; Kim AS; Freedman RA; Miller PG
    J Natl Cancer Inst; 2023 Aug; 115(8):981-988. PubMed ID: 37042724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of clonal hematopoiesis as driver of therapy-related myeloid neoplasms after autologous stem cell transplantation.
    Gramegna D; Bertoli D; Cattaneo C; Almici C; Re A; Belotti A; Borlenghi E; Lanzi G; Archetti S; Verardi R; Brugnoni D; Sciumè M; Daffini R; Roccaro AM; Tucci A; Rossi G
    Ann Hematol; 2022 Jun; 101(6):1227-1237. PubMed ID: 35380239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Cancer Therapy-Related Clonal Hematopoiesis Driver Gene
    Yura Y; Miura-Yura E; Katanasaka Y; Min KD; Chavkin N; Polizio AH; Ogawa H; Horitani K; Doviak H; Evans MA; Sano M; Wang Y; Boroviak K; Philippos G; Domingues AF; Vassiliou G; Sano S; Walsh K
    Circ Res; 2021 Sep; 129(6):684-698. PubMed ID: 34315245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy.
    Werner RA; Ilhan H; Lehner S; Papp L; Zsótér N; Schatka I; Muegge DO; Javadi MS; Higuchi T; Buck AK; Bartenstein P; Bengel F; Essler M; Lapa C; Bundschuh RA
    Mol Imaging Biol; 2019 Jun; 21(3):582-590. PubMed ID: 30014345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clonal hematopoiesis and risk for hematologic malignancy.
    Warren JT; Link DC
    Blood; 2020 Oct; 136(14):1599-1605. PubMed ID: 32736382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fitness Landscape of Clonal Hematopoiesis Under Selective Pressure of Immune Checkpoint Blockade.
    Miller PG; Gibson CJ; Mehta A; Sperling AS; Frederick DT; Manos MP; Miao B; Hacohen N; Hodi FS; Boland GM; Ebert BL
    JCO Precis Oncol; 2020; 4():. PubMed ID: 33015529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer therapy shapes the fitness landscape of clonal hematopoiesis.
    Bolton KL; Ptashkin RN; Gao T; Braunstein L; Devlin SM; Kelly D; Patel M; Berthon A; Syed A; Yabe M; Coombs CC; Caltabellotta NM; Walsh M; Offit K; Stadler Z; Mandelker D; Schulman J; Patel A; Philip J; Bernard E; Gundem G; Ossa JEA; Levine M; Martinez JSM; Farnoud N; Glodzik D; Li S; Robson ME; Lee C; Pharoah PDP; Stopsack KH; Spitzer B; Mantha S; Fagin J; Boucai L; Gibson CJ; Ebert BL; Young AL; Druley T; Takahashi K; Gillis N; Ball M; Padron E; Hyman DM; Baselga J; Norton L; Gardos S; Klimek VM; Scher H; Bajorin D; Paraiso E; Benayed R; Arcila ME; Ladanyi M; Solit DB; Berger MF; Tallman M; Garcia-Closas M; Chatterjee N; Diaz LA; Levine RL; Morton LM; Zehir A; Papaemmanuil E
    Nat Genet; 2020 Nov; 52(11):1219-1226. PubMed ID: 33106634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Sabet A; Ezziddin K; Pape UF; Ahmadzadehfar H; Mayer K; Pöppel T; Guhlke S; Biersack HJ; Ezziddin S
    J Nucl Med; 2013 Nov; 54(11):1857-61. PubMed ID: 24009272
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Kahn JD; Miller PG; Silver AJ; Sellar RS; Bhatt S; Gibson C; McConkey M; Adams D; Mar B; Mertins P; Fereshetian S; Krug K; Zhu H; Letai A; Carr SA; Doench J; Jaiswal S; Ebert BL
    Blood; 2018 Sep; 132(11):1095-1105. PubMed ID: 29954749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Environmental influences on clonal hematopoiesis.
    King KY; Huang Y; Nakada D; Goodell MA
    Exp Hematol; 2020 Mar; 83():66-73. PubMed ID: 31893524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.